FluoroPharma Medical, Inc. (OTCQB: FPMI) engages in the discovery, development and commercialization of proprietary medical diagnostic imaging products. The company’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, amyloid plaque in Alzheimer’s disease and agents for detection of certain types of cancer.
At Seeking Alpha, contributor MissionIR writes that for a developing business to be considered valuable, it needs to "present products that have unique benefits not found elsewhere, providing a decided advantage in the marketplace." He argues that FluoroPharma is such a company, writing that "the products that FluoroPharma is developing have distinct advantages in their ability to highlight critical processes that point to developing cardiovascular disease, sometimes called coronary artery disease (CAD), the country's number one killer, at its earliest stages."
He goes on to elaborate on the company's 3 main products - CardioPET for the assessment of myocardial metabolism, BFPET for the assessment of blood flow for CAD, and VasoPET for the detection of vulnerable plaque in CAD (currently in preclinical development) - as well as their unique advantages.